GO:0140101 catalytic activity, acting on a tRNA: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140101 (catalytic activity, acting on a tRNA) is a molecular function term describing any catalytic activity that modifies a tRNA molecule.
• Enzymes in this class include tRNA methyltransferases such as METTL1-WDR4, aminoacyl-tRNA synthetases, tRNA deaminases (ADAT), and tRNA-modifying enzymes that tune translation and stress responses.
• tRNA modification enzymes can act as regulatory nexuses that influence bacterial stress responses and virulence, making them attractive antibacterial targets.
• Dysregulation of tRNA-modifying enzymes is linked to cancer, neurological disorders, and mitochondrial disease, positioning GO:0140101 as a disease-relevant functional node.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal interrogation of tRNA-modifying enzymes in human cells and animal models.
• Studying GO:0140101 requires integrated methods such as Ribo-seq, tRNA sequencing, mass spectrometry, and biochemical tRNA modification assays.
Description
GO:0140101, catalytic activity, acting on a tRNA, is a Gene Ontology molecular function term that captures enzymes whose catalytic action modifies a tRNA molecule. This term is intentionally broad: it includes tRNA methyltransferases, aminoacyl-tRNA synthetases, tRNA deaminases, and other enzymes that add, remove, or rearrange chemical groups on tRNA substrates. Because tRNAs are central to translation, any catalytic modification of tRNA can directly reshape the proteome and cellular physiology. Researchers studying translation, RNA modification, and tRNA biology use GO:0140101 to annotate and compare enzymes that act on tRNA, from bacterial stress-response regulators to human oncogenic modifiers. The term is also a practical entry point for functional genomics: once a gene is annotated to GO:0140101, knockout, point-mutation, and knock-in models can be designed to test its role in translation and disease.
catalytic activity, acting on a tRNA At A Glance
| GO ID | GO:0140101 |
|---|---|
| GO term | catalytic activity, acting on a tRNA |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Catalytic activity that acts to modify a tRNA. |
| Major function | Enzymatic modification of tRNA molecules, including methylation, deamination, and aminoacylation. |
| Representative enzymes | METTL1-WDR4 tRNA methyltransferase, aminoacyl-tRNA synthetases, ADAT tRNA deaminases, and bacterial tRNA-modifying enzymes. |
| Substrate | tRNA molecules, including specific tRNA species and anticodon loops. |
| Disease relevance | Cancer, neurological disorders, mitochondrial disease, and bacterial virulence. |
What Is GO:0140101?
In plain terms, GO:0140101 describes any enzyme that chemically changes a tRNA. The official QuickGO definition states that it is a catalytic activity that acts to modify a tRNA. This includes methylation, deamination, aminoacylation, and other covalent modifications of tRNA bases or the tRNA backbone. The term is a molecular function, not a biological process or cellular component, so it is used to annotate the enzymatic activity itself rather than the pathway or location in which the enzyme operates.
Why Is catalytic activity, acting on a tRNA Important in Cell Biology?
GO:0140101 matters because tRNA modification is a fast, reversible way for cells to tune translation in response to stress, growth signals, and infection. Enzymes annotated to this term can determine whether a tRNA is charged, methylated, or deaminated, which in turn affects codon decoding, translation fidelity, and protein output. In bacteria, tRNA-modifying enzymes can act as regulatory nexuses for stress responses and virulence, making them potential drug targets. In humans, mutations or dysregulation of tRNA-modifying enzymes are linked to cancer and neurological disease, so the term is a practical starting point for disease modeling and therapeutic hypothesis generation.
• Controls translation efficiency and fidelity by modifying tRNA bases and anticodon loops.
• Enables rapid cellular adaptation to stress through tunable tRNA modifications.
• Provides a mechanistic link between RNA modification and bacterial virulence.
• Is directly relevant to cancer biology through enzymes such as METTL1-WDR4.
• Supports mitochondrial and neurological disease research via tRNA deaminases and synthetases.
• Offers antibacterial target opportunities because tRNA modification enzymes are essential in pathogens.
• Facilitates synthetic biology and genetic code expansion through engineered tRNA-modifying enzymes.
• Serves as a functional annotation hub for interpreting CRISPR screens and omics data.
• Connects RNA catalysis principles to translational control.
• Enables cross-species comparative studies of tRNA modification from bacteria to humans.
What Happens During catalytic activity, acting on a tRNA?
Substrate recognition and tRNA binding
In simple terms: The enzyme first finds and grabs the correct tRNA.
Enzymes in GO:0140101 must recognize specific tRNA features, such as the anticodon loop, acceptor stem, or variable loop, to achieve substrate specificity. For example, METTL1-WDR4 recognizes tRNA substrates through a composite binding surface that positions the target base for methylation. Aminoacyl-tRNA synthetases use identity elements in the tRNA to discriminate between closely related tRNA species. This recognition step is a major determinant of whether a tRNA is modified correctly or mis-modified.
Catalytic modification of tRNA
In simple terms: The enzyme then performs the chemical change on the tRNA.
Once bound, the enzyme catalyzes a covalent modification of the tRNA, such as methylation, deamination, or aminoacylation. METTL1-WDR4 catalyzes N7-methylguanosine modification of tRNA, a mark that influences translation and stability. ADAT enzymes deaminate adenosine to inosine in tRNA, altering decoding capacity. Aminoacyl-tRNA synthetases attach amino acids to the tRNA 3' end, a prerequisite for translation. These reactions are often metal-dependent or use cofactors such as S-adenosylmethionine.
tRNA modification and translation coupling
In simple terms: The modified tRNA then feeds into translation.
Modified tRNAs are used by the ribosome to decode mRNA, and the modification state can change codon preference, translation speed, and fidelity. tRNA modification enzymes can therefore act as tunable regulators of the proteome. In bacteria, tRNA modification enzymes can be rewired during stress to favor translation of stress-response proteins. In synthetic systems, engineered tRNA-modifying enzymes can generate nonproteinogenic aminoacyl-tRNAs for genetic code expansion.
Regulation and feedback
In simple terms: The cell can dial the enzyme up or down as needed.
The activity of tRNA-modifying enzymes is regulated at multiple levels, including expression, localization, and post-translational modification. Bacterial tRNA modification enzymes can be induced under stress and can influence virulence gene expression. In eukaryotes, tRNA modification enzymes such as METTL1-WDR4 are often upregulated in cancer and can be targeted for therapeutic intervention. Feedback from translation status can also influence tRNA modification levels.
Key Genes Involved in GO:0140101 catalytic activity, acting on a tRNA
The following genes and proteins are representative members or direct interaction partners of enzymes annotated to GO:0140101, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL1 | Catalytic subunit of tRNA N7-methylguanosine methyltransferase | Cancer, translation control, and tRNA modification studies |
| WDR4 | Essential partner of METTL1 for tRNA methylation | Structural and functional studies of tRNA methyltransferases |
| ADAT1 | tRNA adenosine deaminase acting on tRNA | Neurological and regeneration research |
| ADAT2 | tRNA adenosine deaminase acting on tRNA | tRNA editing and decoding studies |
| ADAT3 | tRNA adenosine deaminase acting on tRNA | Neurological disease and tRNA modification |
| AARS1 | Alanyl-tRNA synthetase, aminoacylates tRNA | Translation fidelity and disease modeling |
| AARS2 | Mitochondrial alanyl-tRNA synthetase | Mitochondrial disease research |
| GARS1 | Glycyl-tRNA synthetase | Charcot-Marie-Tooth disease and translation |
| YARS1 | Tyrosyl-tRNA synthetase | Cancer and immune signaling |
| MARS1 | Methionyl-tRNA synthetase | Translation initiation and disease |
| IARS1 | Isoleucyl-tRNA synthetase | Translation fidelity and disease |
| LARS1 | Leucyl-tRNA synthetase | mTOR signaling and translation control |
| KARS1 | Lysyl-tRNA synthetase | Neurological disease and translation |
| SARS1 | Seryl-tRNA synthetase | Translation and disease modeling |
| TARS1 | Threonyl-tRNA synthetase | Translation and stress responses |
| VARS1 | Valyl-tRNA synthetase | Translation fidelity and disease |
| FTSJ1 | tRNA methyltransferase | Intellectual disability and tRNA modification |
How Is catalytic activity, acting on a tRNA Regulated?
The activity of enzymes in GO:0140101 is regulated at transcriptional, post-transcriptional, and post-translational levels. In bacteria, tRNA modification enzymes can be induced under stress conditions and act as tunable regulatory nexuses for virulence. In eukaryotes, tRNA methyltransferases such as METTL1-WDR4 are often upregulated in cancer and can be regulated by growth signaling pathways. Aminoacyl-tRNA synthetases are regulated by mTOR and other nutrient-sensing pathways to match translation demand. These regulatory layers allow cells to rapidly adjust tRNA modification and charging in response to environmental changes.
catalytic activity, acting on a tRNA and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL1 | Cancer, translation control | Knockout and overexpression in cancer cell lines |
| WDR4 | Cancer, tRNA methylation | Knock-in of patient variants and structural studies |
| ADAT3 | Neurodevelopmental disorder | Knockout and point-mutation models in neurons |
| AARS2 | Mitochondrial disease | Knockout and knock-in in patient fibroblasts |
| GARS1 | Charcot-Marie-Tooth disease | Point-mutation knock-in in mouse models |
Cancer
Dysregulation of tRNA-modifying enzymes is increasingly recognized in cancer. METTL1-WDR4-mediated tRNA methylation promotes translation of oncogenic transcripts and is associated with tumor progression. Targeting tRNA modification enzymes is therefore an active area of cancer therapeutic research.
Neurological and neurodevelopmental disorders
Mutations in tRNA deaminases and aminoacyl-tRNA synthetases cause neurological phenotypes, including intellectual disability and neurodegeneration. ADAT3 mutations are linked to neurodevelopmental disorders, and tRNA modification defects can impair translation in neurons. These findings position GO:0140101 enzymes as disease-relevant nodes.
Bacterial virulence and infectious disease
Bacterial tRNA-modifying enzymes can act as regulatory nexuses for stress responses and virulence, making them potential antibacterial targets. Inhibiting these enzymes could attenuate pathogen fitness without directly killing the bacterium, potentially reducing resistance pressure.
Mitochondrial disease
Mitochondrial aminoacyl-tRNA synthetases are essential for mitochondrial translation, and mutations in these enzymes cause mitochondrial disease. Studying GO:0140101 enzymes in mitochondria can reveal mechanisms of OXPHOS deficiency and guide therapeutic development.
From catalytic activity, acting on a tRNA-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the enzyme essential for translation? | CRISPR knockout cell lines |
| Does a disease variant alter catalytic activity? | Point-mutation knock-in |
| Can the enzyme be tagged for localization studies? | Tagged knock-in |
| Does overexpression drive oncogenic translation? | Overexpression cell models |
| Does the enzyme regulate bacterial virulence? | Bacterial knockout and overexpression |
| Can the enzyme be engineered for synthetic biology? | Engineered tRNA-modifying enzyme variants |
How to Study the catalytic activity, acting on a tRNA Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and translation efficiency | Proteome-wide effects of tRNA modification |
| tRNA sequencing | tRNA abundance and modification signatures | tRNA modification profiling |
| Mass spectrometry | tRNA modification identity and stoichiometry | Biochemical validation of enzyme activity |
| CRISPR knockout screens | Gene essentiality and fitness | Discovery of tRNA-modifying enzyme dependencies |
| Cryo-EM | Enzyme-tRNA complex structure | Mechanistic studies of tRNA methyltransferases |
| Fluorescence imaging | Subcellular localization | Dynamic tracking of tRNA-modifying enzymes |
| In vitro enzyme assays | Kinetic parameters and cofactor requirements | Mechanistic characterization |
| Bioinformatics | Sequence and structural conservation | Annotation and comparative genomics |
Ribo-seq and tRNA sequencing
Ribo-seq measures ribosome occupancy and translation efficiency, which can reveal how tRNA modification enzymes shape the proteome. tRNA sequencing methods detect modification-induced signatures and can quantify tRNA abundance and charging. Combining these methods provides a systems-level view of GO:0140101 function.
Mass spectrometry and biochemical assays
Mass spectrometry can identify and quantify tRNA modifications directly, providing a readout of enzyme activity. In vitro biochemical assays using purified enzymes and tRNA substrates can determine kinetic parameters and cofactor requirements. These approaches are essential for mechanistic studies of GO:0140101 enzymes.
CRISPR screens and functional genomics
CRISPR knockout screens can identify tRNA-modifying enzymes required for cell growth, stress survival, or drug resistance. Focused screens targeting GO:0140101 genes can reveal context-specific dependencies in cancer or infection models. These screens generate hypotheses that can be validated with targeted models.
Structural biology and imaging
Cryo-EM and X-ray crystallography have revealed how enzymes such as METTL1-WDR4 recognize and modify tRNA. Fluorescence imaging of tagged tRNA-modifying enzymes can show their subcellular localization and dynamics. Structural and imaging data complement functional studies to build a complete mechanistic picture.
How CRISPR Can Be Used to Study GO:0140101 catalytic activity, acting on a tRNA
Knockout
CRISPR knockout of genes annotated to GO:0140101 can reveal whether the enzyme is essential for translation, stress survival, or disease phenotypes. For example, knocking out METTL1 or WDR4 reduces tRNA methylation and alters translation of specific transcripts. Knockout models are also useful for testing bacterial virulence dependence on tRNA-modifying enzymes.
Point Mutation
Point-mutation knock-in models can dissect catalytic residues and disease-associated variants of tRNA-modifying enzymes. For example, mutating the catalytic site of METTL1 can separate its catalytic activity from scaffolding functions. Point mutations in aminoacyl-tRNA synthetases can model Charcot-Marie-Tooth disease and mitochondrial disease.
Knock-in
Knock-in of tagged or reporter alleles enables localization, interaction, and stability studies of GO:0140101 enzymes. Tagged knock-in of METTL1-WDR4 can be used for proteomics and imaging. Knock-in of patient variants can model disease mechanisms in isogenic cell lines.
Overexpression
Overexpression of tRNA-modifying enzymes can test sufficiency for oncogenic transformation or stress resistance. Overexpression of METTL1 promotes translation of oncogenic transcripts and is observed in cancers. Overexpression models are also useful for synthetic biology applications such as genetic code expansion.
How EDITGENE Supports catalytic activity, acting on a tRNA Research
Researchers studying catalytic activity, acting on a tRNA-related genes often need to determine whether a candidate gene is causally involved in translation control, stress response, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for GO:0140101 genes, enabling functional validation from hypothesis to publication.
Contact EDITGENE today to design your custom CRISPR model for catalytic activity, acting on a tRNA research.
Frequently Asked Questions About catalytic activity, acting on a tRNA
What is GO:0140101?
GO:0140101 is a Gene Ontology molecular function term defined as catalytic activity that acts to modify a tRNA.
What genes are involved in catalytic activity, acting on a tRNA?
Representative genes include METTL1, WDR4, ADAT1, ADAT2, ADAT3, and multiple aminoacyl-tRNA synthetases such as AARS1, GARS1, and YARS1.
What diseases are linked to tRNA-modifying enzymes?
tRNA-modifying enzymes are linked to cancer, neurological disorders, mitochondrial disease, and bacterial virulence.
How do tRNA methyltransferases work?
tRNA methyltransferases such as METTL1-WDR4 bind specific tRNA substrates and transfer methyl groups to target bases, influencing translation.
What is the role of aminoacyl-tRNA synthetases in GO:0140101?
Aminoacyl-tRNA synthetases catalyze the attachment of amino acids to tRNA, a prerequisite for translation, and are annotated to GO:0140101.
Can CRISPR be used to study tRNA-modifying enzymes?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models are widely used to study tRNA-modifying enzymes.
What methods are used to study tRNA modifications?
Common methods include Ribo-seq, tRNA sequencing, mass spectrometry, biochemical assays, and structural biology.
Why are tRNA-modifying enzymes important in bacteria?
Bacterial tRNA-modifying enzymes can act as regulatory nexuses for stress responses and virulence, making them potential drug targets.
What is the connection between tRNA modifications and cancer?
tRNA modification enzymes such as METTL1-WDR4 are often upregulated in cancer and promote translation of oncogenic transcripts.
How can I model GO:0140101 genes in the lab?
You can use CRISPR knockout, point-mutation knock-in, tagged knock-in, or overexpression cell models, depending on your research question.
Conclusion
GO:0140101, catalytic activity, acting on a tRNA, defines a broad and biologically important class of enzymes that modify tRNA to control translation, stress responses, and disease. From tRNA methyltransferases such as METTL1-WDR4 to aminoacyl-tRNA synthetases and deaminases, these enzymes are central to proteome regulation and are linked to cancer, neurological disorders, and infection. Studying GO:0140101 with CRISPR models and integrated omics methods offers a powerful route to mechanistic and therapeutic insights.
References
- 1. Ruiz-Arroyo VM et al.. 2023. Structures and mechanisms of tRNA methylation by METTL1-WDR4.. Nature 613(7943):383-390 PMID: 36599982
- 2. Wilson TJ et al.. 2021. The potential versatility of RNA catalysis.. Wiley Interdiscip Rev RNA 12(5):e1651 PMID: 33949113
- 4. Perona JJ et al.. 2014. Synthetic and editing mechanisms of aminoacyl-tRNA synthetases.. Top Curr Chem 344:1-41 PMID: 23852030
- 5. Yoon YB et al.. 2021. Identification and expression of adenosine deaminases acting on tRNA (ADAT) during early tail regeneration of the earthworm.. Genes Genomics 43(3):295-301 PMID: 33575975
- 6. Lu W et al.. 2024. An anticodon-sensing T-boxzyme generates the elongator nonproteinogenic aminoacyl-tRNA in situ of a custom-made translation system for incorporation.. Nucleic Acids Res 52(7):3938-3949 PMID: 38477328
- 7. Parra-Meneses V et al.. 2024. Exploring the catalytic mechanism of the 10-23 DNAzyme: insights from pH-rate profiles.. Org Biomol Chem 22(33):6833-6840 PMID: 39115293
- 8. Fleming BA et al.. 2022. A tRNA modifying enzyme as a tunable regulatory nexus for bacterial stress responses and virulence.. Nucleic Acids Res 50(13):7570-7590 PMID: 35212379
